Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NASDAQ:SVRA NASDAQ:TRDA NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.74-2.1%$2.65$1.84▼$3.43$1.04B0.891.51 million shs2.15 million shsSVRASavara$5.09-4.0%$5.31$1.98▼$7.01$1.09B0.261.37 million shs1.20 million shsTRDAEntrada Therapeutics$6.37-9.0%$10.45$4.93▼$16.45$271.74M-0.26485,332 shs195,030 shsXERSXeris Biopharma$6.18+0.5%$6.10$4.30▼$10.08$1.06B0.781.52 million shs1.03 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+3.32%-1.41%+6.46%+8.95%+45.08%SVRASavara+0.95%+4.13%+0.95%+0.57%+112.85%TRDAEntrada Therapeutics+6.38%+2.64%-55.56%-44.36%-11.73%XERSXeris Biopharma+4.41%-2.69%-1.28%+5.85%+38.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.74-2.1%$2.65$1.84▼$3.43$1.04B0.891.51 million shs2.15 million shsSVRASavara$5.09-4.0%$5.31$1.98▼$7.01$1.09B0.261.37 million shs1.20 million shsTRDAEntrada Therapeutics$6.37-9.0%$10.45$4.93▼$16.45$271.74M-0.26485,332 shs195,030 shsXERSXeris Biopharma$6.18+0.5%$6.10$4.30▼$10.08$1.06B0.781.52 million shs1.03 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+3.32%-1.41%+6.46%+8.95%+45.08%SVRASavara+0.95%+4.13%+0.95%+0.57%+112.85%TRDAEntrada Therapeutics+6.38%+2.64%-55.56%-44.36%-11.73%XERSXeris Biopharma+4.41%-2.69%-1.28%+5.85%+38.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 2.20Hold$2.30-16.06% DownsideSVRASavara 2.88Moderate Buy$10.1499.27% UpsideTRDAEntrada Therapeutics 2.50Moderate Buy$18.25186.50% UpsideXERSXeris Biopharma 2.43Hold$10.8074.76% UpsideCurrent Analyst Ratings BreakdownLatest TRDA, SVRA, CRON, and XERS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026CRONCronos Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/12/2026CRONCronos Group TD SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026XERSXeris Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/8/2026TRDAEntrada Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.005/8/2026TRDAEntrada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/24/2026SVRASavara OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.00 ➝ $11.004/21/2026SVRASavara Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026TRDAEntrada Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $23.004/1/2026TRDAEntrada Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight3/27/2026TRDAEntrada Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/16/2026SVRASavara William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$146.59M6.97$0.01 per share223.34$3.00 per share0.91SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ATRDAEntrada Therapeutics$25.42M9.73N/AN/A$8.01 per share0.80XERSXeris Biopharma$291.85M3.66$0.10 per share61.40$0.08 per share77.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$9.45M$0.01N/AN/AN/A-1.14%-1.26%-1.20%8/6/2026 (Estimated)SVRASavara-$118.84M-$0.56N/AN/AN/AN/A-87.19%-66.42%8/12/2026 (Estimated)TRDAEntrada Therapeutics-$143.75M-$3.99N/AN/AN/A-2,895.05%-51.22%-42.20%8/5/2026 (Estimated)XERSXeris Biopharma$550K$0.06103.0018.18N/A3.81%735.00%3.24%8/6/2026 (Estimated)Latest TRDA, SVRA, CRON, and XERS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SVRASavara-$0.14-$0.15-$0.01-$0.15$0.50 millionN/A5/11/2026Q1 2026CRONCronos Group$0.01$0.01N/A$0.04$42.20 million$58.97 million5/7/2026Q1 2026TRDAEntrada Therapeutics-$1.06-$0.95+$0.11-$0.95$2.92 million$0.88 million5/7/2026Q1 2026XERSXeris Biopharma-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 million3/13/2026Q4 2025SVRASavara-$0.12-$0.13-$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A21.8720.73SVRASavara0.1713.4713.47TRDAEntrada TherapeuticsN/A13.9013.90XERSXeris Biopharma17.002.121.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%SVRASavara87.93%TRDAEntrada Therapeutics86.39%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.80%SVRASavara5.30%TRDAEntrada Therapeutics9.49%XERSXeris Biopharma4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450373.03 million345.21 millionOptionableSVRASavara20204.93 million194.07 millionOptionableTRDAEntrada Therapeutics11038.82 million35.14 millionOptionableXERSXeris Biopharma290172.64 million165.13 millionOptionableTRDA, SVRA, CRON, and XERS HeadlinesRecent News About These CompaniesXeris Biopharma Shareholders Elect Directors and Ratify Auditor3 hours ago | tipranks.comXeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 SharesJune 3 at 6:13 AM | insidertrades.comXeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway RightMay 30, 2026 | seekingalpha.comUBS Group AG Reduces Position in Xeris Biopharma Holdings, Inc. $XERSMay 22, 2026 | marketbeat.comShareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) EarningsMay 15, 2026 | finance.yahoo.comXeris Biopharma Quality Draws Market Attention Through Growth SignalsMay 15, 2026 | kalkinemedia.comKVanguard Group Inc. Buys 1,358,760 Shares of Xeris Biopharma Holdings, Inc. $XERSMay 14, 2026 | marketbeat.comXeris Biopharma Q3 EPS Forecast Decreased by HC WainwrightMay 11, 2026 | marketbeat.comResults: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise ProfitMay 9, 2026 | uk.finance.yahoo.comXeris Biopharma Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comXeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's ChangedMay 8, 2026 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Posts Earnings ResultsMay 7, 2026 | marketbeat.comXeris (XERS) Q1 2026 Earnings Call TranscriptMay 7, 2026 | aol.comAXeris Biopharma: Q1 Earnings SnapshotMay 7, 2026 | wtop.comWXeris Biopharma Reports First Quarter 2026 Financial ResultsMay 7, 2026 | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comXeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 7, 2026 | zacks.comXeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay RevealedApril 23, 2026 | quiverquant.comQXeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026April 23, 2026 | businesswire.comXeris Biopharma Announces Board Transition as Director RetiresApril 21, 2026 | tipranks.comXeris Biopharma Holdings, Inc.April 16, 2026 | edition.cnn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Stocks Rallying on Micron's Price Boost: Substance or Hype?By Dan Schmidt | May 28, 2026The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 2026Micron Investors Face a High-Stakes Moment After the Latest RallyBy Thomas Hughes | May 13, 2026Micron’s $1 Trillion Memory Melt-UpBy Jeffrey Neal Johnson | May 27, 2026TRDA, SVRA, CRON, and XERS Company DescriptionsCronos Group NASDAQ:CRON$2.74 -0.06 (-2.14%) Closing price 04:00 PM EasternExtended Trading$2.76 +0.01 (+0.55%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Savara NASDAQ:SVRA$5.09 -0.21 (-3.96%) Closing price 04:00 PM EasternExtended Trading$5.10 +0.00 (+0.10%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Entrada Therapeutics NASDAQ:TRDA$6.37 -0.63 (-9.00%) Closing price 04:00 PM EasternExtended Trading$5.25 -1.12 (-17.65%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Xeris Biopharma NASDAQ:XERS$6.18 +0.03 (+0.49%) Closing price 04:00 PM EasternExtended Trading$6.17 -0.01 (-0.16%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
